Older hematopoietic stem cell transplant survivors appeared 2.6 times more likely to report severe, nonminor or life-threatening pain than cancer-free siblings, according to results of a prospective study published in Cancer.
Overall, nearly 40% of older HSCT survivors followed for a median 5 years reported having pain, researchers noted.
This activity is supported by educational grants from AbbVie, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Takeda Oncology; and Verastem, Inc..
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2020 Healio All Rights Reserved.